04.10.17
Henning Steinhagen has been named as president, research and development operations. He will continue in his existing role of site-head at Aptuit, Verona, Italy while assuming oversight of Aptuit global operations.
His additional responsibilities will include line management of Aptuit’s Oxford and Potters Bar sites, which provide API, process chemistry and preformulation services.
Dr. Steinhagen joined Aptuit in June 2016 from Grünenthal, where he was senior vice president, and head of global drug discovery, following positions of increasing responsibility at Sanofi and Bayer.
“We are delighted to welcome Henning to the newly created position of president, research and development operations. Aptuit continues to grow, driven by our market leading position as the premier partner research organization (PRO), providing fully integrated discovery and early development solutions,” said Jonathan Goldman, chief executive officer, Aptuit. “Consolidation of reporting responsibilities within our scientific operations enhances the quality of our integrated CMC offering, whilst shortening timelines and reducing costs for our biopharma partners.”
His additional responsibilities will include line management of Aptuit’s Oxford and Potters Bar sites, which provide API, process chemistry and preformulation services.
Dr. Steinhagen joined Aptuit in June 2016 from Grünenthal, where he was senior vice president, and head of global drug discovery, following positions of increasing responsibility at Sanofi and Bayer.
“We are delighted to welcome Henning to the newly created position of president, research and development operations. Aptuit continues to grow, driven by our market leading position as the premier partner research organization (PRO), providing fully integrated discovery and early development solutions,” said Jonathan Goldman, chief executive officer, Aptuit. “Consolidation of reporting responsibilities within our scientific operations enhances the quality of our integrated CMC offering, whilst shortening timelines and reducing costs for our biopharma partners.”
